COLYTE w. FLAVOR PACKS Rx
Generic Name and Formulations:
Polyethylene glycol 3350 60g, sodium chloride 1.46g, potassium chloride 0.745g, sodium bicarbonate 1.68g, sodium sulfate 5.68g, flavor 0.851g/pack (orange, lemon lime, cherry); per liter of soln; pwd for reconstitution (add 1 flavor pack before reconstitution).
Indications for COLYTE w. FLAVOR PACKS:
Bowel cleansing before colonoscopy or barium enema exam.
After fasting for >3hrs, 240mL orally every 10mins or 20–30mL/min by NG tube until fecal discharge is clear. Usual dose 3–4L. Only clear liquids until exam.
GI obstruction or perforation. Gastric retention. Toxic colitis. Toxic megacolon. Ileus.
Severe ulcerative colitis. Impaired gag reflex. Semi- or unconsciousness. Risk of aspiration or regurgitation. Correct fluid and electrolyte abnormalities prior to initiation. Increased risk of arrhythmias (eg, history of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF or cardiomyopathy); do pre-dose and post-colonoscopy ECGs. History of seizures. Rule out GI obstruction or perforation. Maintain adequate hydration. Renal impairment. Pregnancy (Cat.C). Nursing mothers.
Concomitant drugs that may increase the risk of fluid and electrolyte disturbances or adverse events. Drugs administered within 1hr of start of Colyte may not be absorbed. Increased risk of ischemic colitis with concomitant stimulant laxatives.
Isosmotic bowel cleanser.
Nausea, abdominal fullness or bloating, cramps, vomiting, anal irritation; serious: colonic mucosal ulceration, ischemic colitis; rare: arrhythmias.
Colyte w. Flavor Packs—4L (disposable jug w. 3 flavor packs)
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|